18889881171
Kalkine 0
countryflagUS

Bluejay Diagnostics Inc

Healthcare US BJDX

1.77USD
-0.01(0.56%)

Last update at 2025-05-16T16:36:00Z

Day Range

1.721.86
LowHigh

52 Week Range

3.031372.00
LowHigh

Fundamentals

  • Previous Close 1.78
  • Market Cap2.24M
  • Volume19636
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.73763M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.05M
  • Diluted EPS TTM-804.0

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -9.29695M -3.48830M -1.15829M -0.81984M
Minority interest - - - -
Net income -9.22789M -3.72969M -1.12572M -0.75772M
Selling general administrative 4.76M 1.79M 0.60M 0.88M
Selling and marketing expenses 0.45M 0.29M 0.07M 0.29M
Gross profit 0.05M - - -
Reconciled depreciation 0.31M 0.15M 0.16M 0.14M
Ebit -9.31778M -3.23016M -1.19639M -1.63141M
Ebitda -9.05964M -3.13551M -1.09892M -1.49828M
Depreciation and amortization 0.26M 0.09M 0.10M 0.13M
Non operating income net other - - - -
Operating income -9.31778M -3.23016M -1.19639M -1.63141M
Other operating expenses 9.57M 3.16M 1.20M 1.63M
Interest expense -0.02083M 0.37M 0.03M 0.00000M
Tax provision - - - -
Interest income - - - -
Net interest income 0.00000M -0.36746M -0.02700M 0.05M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.06906M 0.24M -0.03257M -0.06213M
Total revenue 0.25M 0.00007M 0.00000M 0.00000M
Total operating expenses 9.37M 3.16M 1.20M 1.63M
Cost of revenue 0.20M - - -
Total other income expense net 0.02M -0.25814M 0.04M 0.81M
Discontinued operations - - - -
Net income from continuing ops -9.29695M -3.48830M -1.15829M -0.81984M
Net income applicable to common shares -9.29695M -3.48830M -1.15829M -0.81984M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 4.87M 13.52M 21.02M 1.52M 0.92M
Intangible assets - 0.00446M 0.00462M 0.00462M 0.00462M
Earning assets - - - - -
Other current assets 0.71M 1.67M 1.61M 0.05M 0.07M
Total liab 1.97M 1.98M 0.64M 5.72M 3.85M
Total stockholder equity 2.89M 11.54M 20.38M -4.20617M -2.93244M
Deferred long term liab - - - - -
Other current liab 1.11M 0.84M 0.34M 0.16M 0.20M
Common stock 0.00012M 0.00202M 0.00201M 0.00032M 0.00032M
Capital stock 0.00012M 0.00202M 0.00201M 0.00032M 0.00032M
Retained earnings -26.95099M -16.99710M -7.69479M -4.20649M -2.93275M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 0.04M 0.02M - -
Cash 2.21M 10.11M 19.05M 0.91M 0.10M
Cash and equivalents - - - - -
Total current liabilities 1.77M 1.64M 0.64M 1.85M 0.58M
Current deferred revenue - - - 0.26M 0.09M
Net debt -1.83841M -9.62237M -19.04778M 0.14M 0.97M
Short term debt 0.17M 0.17M - 1.06M 0.27M
Short long term debt - - - 1.06M 0.27M
Short long term debt total 0.37M 0.49M - 1.06M 1.07M
Other stockholder equity 29.85M 28.54M 28.07M - -
Property plant equipment - 1.70M 0.34M 0.46M 0.62M
Total current assets 2.96M 11.79M 20.66M 1.06M 0.30M
Long term investments - - - - -
Net tangible assets - 11.54M 20.38M -4.20617M -2.93244M
Short term investments - - - - -
Net receivables 0.04M - - 0.00796M 0.00064M
Long term debt - - - - 0.80M
Inventory - - 0.00000M 0.08M 0.12M
Accounts payable 0.49M 0.64M 0.30M 0.37M 0.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -21.01887M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.29M 0.03M 0.02M - -
Deferred long term asset charges - - - - -
Non current assets total 1.91M 1.73M 0.36M 0.46M 0.62M
Capital lease obligations 0.35M 0.51M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -1.19927M -0.02395M 0.00000M -0.00602M
Change to liabilities 0.30M -0.07915M 0.35M -0.02521M
Total cashflows from investing activities -1.19927M -0.02395M -0.02395M -0.00602M
Net borrowings -0.00080M 4.20M 0.27M -0.26500M
Total cash from financing activities 0.00808M 22.53M 1.33M 1.51M
Change to operating activities 0.28M -1.49092M 0.21M -0.04855M
Net income -9.29695M -3.48830M -1.15829M -0.81984M
Change in cash -8.93279M 18.14M 0.82M -0.18434M
Begin period cash flow 19.05M 0.91M 0.10M 0.28M
End period cash flow 10.11M 19.05M 0.91M 0.10M
Total cash from operating activities -7.74159M -4.36676M -0.50871M -1.69012M
Issuance of capital stock 0.00000M 18.86M 1.06M 1.68M
Depreciation 0.31M 0.15M 0.16M 0.14M
Other cashflows from investing activities - - - -
Dividends paid - -0.01767M - -
Change to inventory 0.00000M 0.08M 0.04M -0.10388M
Change to account receivables - 0.00000M 0.00064M -0.00064M
Sale purchase of stock - 0.02M - -
Other cashflows from financing activities -0.02000M 3.97M 1.33M 1.78M
Change to netincome 0.67M 0.46M -0.10373M -0.83497M
Capital expenditures 1.20M 0.02M 0.02M 0.00602M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.58M -1.48531M 0.60M -0.17828M
Stock based compensation 0.43M 0.07M 0.00737M 0.01M
Other non cash items 0.24M 0.22M -0.15353M -0.83994M
Free cash flow -8.94086M -4.39070M -0.50871M -1.69614M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BJDX
Bluejay Diagnostics Inc		 -0.01 0.56% 1.77 - - 54.99 0.32 5.67 -0.096
ABT
Abbott Laboratories		 1.36 1.02% 134.71 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 1.92 0.49% 394.12 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.05 0.06% 86.16 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 1.27 1.21% 106.13 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Bluejay Diagnostics Inc

360 Massachusetts Avenue, Acton, MA, United States, 01720

Key Executives

Name Title Year Born
Mr. Indranil Dey Pres, CEO & Director 1964
Dr. Jason Cook Chief Technology Officer 1982
Mr. Kenneth R. Fisher CPA Chief Financial Officer 1980
Mr. Kevin Vance Chief Commercial Officer 1957
Mark W. Feinberg Chief Medical Advisor NA
Dr. Mark W. Feinberg M.D. Chief Medical Advisor NA
Mr. Indranil Dey Principal Financial, Accounting & Executive Officer, President, CEO and Director 1964
Dr. Jason Cook Chief Technology Officer 1983
Mr. Les DeLuca Vice President of Operations NA
Eryn Graham Marketing Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.